NL

Nanna Luneborg

General Partner at Forbion

Amsterdam, North Holland

Investor
VC

Invests in

Stages:

Series B

Locations:

Denmark

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Research
Healthcare
Start-ups
Negotiation
Biotechnology
Lifesciences
Drug Discovery
Pharmaceutical Industry
Business Strategy
Medical Devices
Due Diligence
Market Analysis
Drug Development
Financial Modeling
Valuation
Venture Capital
Strategy
Life Sciences

Education

  • Master of Business Administration (MBA)

    University of Cambridge

    (2007 - 2008)

  • PhD

    UCL

    (2000 - 2005)

  • BA (1st class)

    University of Oxford

    (1997 - 2000)

  • Certificate in Company Direction

    Institute of Directors (IoD)

    (2013 - 2013)

  • Certificate in Investment Management

    Chartered Institute for Securities & Investments

    (2009 - 2009)

  • Matematisk Studentereksamen (high school diploma)

    Marselisborg Gymnasium

    (1991 - 1994)

Investments

Capstan Therapeutics

Series B

Total Funding: $280M

Noema Pharma

Series B

Total Funding: $110M

Inversago Pharma

Series C

Total Funding: $110M

F2G

Private Equity

Total Funding: $160M

Numab

Series C

Total Funding: $110M

Lava Therapeutics

Series C

Total Funding: $100M

NodThera

Series B

Total Funding: $95M

NBE-Therapeutics

Series B

Total Funding: $20M

Inthera Bioscience

Seed

Total Funding: $20M

Work Experience

Forbion

2021

  • General Partner

    2021

    - General Partner, Forbion Growth Opportunities Fund - Late stage and crossover investments in biotech - Board director of Capstan, BioInvent, F2G, Noema and Inversago (acquired by Novo Nordisk), observer in Numab

Novo Holdings

2012 - 2021

  • Partner

    2018 - 2021

    • Partner in Novo Ventures • Board director in Numab, Lava (LVTX), ReViral (acquired by Pfizer), NodThera and Stargazer • Previous deals as lead investor/board director include NBE Therapeutics (acquired by Boehringer Ingelheim), Inventiva (IVA), Orphazyme (ORPHA), ObsEva (OBSV) and IO Biotech (IOBT)

  • Principal

    2016 - 2017

    • Principal in Novo Ventures

  • Investment Director

    2013 - 2015

    • Investment Director in Novo Seeds • Board member in IO Biotech, Inthera, Glionova, Affinicon, MinervaX, Pcovery, board observer in Galecto, ForEndo

  • Principal

    2012 - 2013

    • Principal in Novo Seeds • Seed stage biotech venture investment in Northern Europe

Apposite Capital

2008 - 2012

  • Associate

    2008 - 2012

    • Investment professional in a healthcare venture fund • Successful exits from both primary and secondary deals, incl Convergence, Ulthera, SureCalm • Multiple deals completed from initial diligence to closing • Various deal structures: primary/secondary investments, spin-out, start-up, management buy-in

Apposite Capital

2008 - 2008

  • Intern

    2008 - 2008

    MBA summer internship

Cisco

2008 - 2008

  • Consulting project

    2008 - 2008

    MBA team consulting project: IP technology in UK healthcare

Aktogen

2007 - 2007

  • Consulting project

    2007 - 2007

    MBA team consulting project on business model and strategy for a biotech start-up

Cancer Research UK

2005 - 2007

  • Senior Business Intelligence Analyst

    2006 - 2007

    • Business Intelligence on performance metrics across £315 M research portfolio • Strategic evaluation to CEO

  • Research Manager

    2005 - 2006

    • Financial and scientific analyses of research portfolio across organisation • Liaison with principal investigators and research organisations in UK and US

University College London

2000 - 2004

  • Graduate Research Associate

    2000 - 2004

    Research project leading to PhD thesis in development neuroscience

IIR

1996 - 1997

  • Marketing Manager

    1996 - 1997

    Managed marketing campaigns for international business conference and training group